Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Verrica Pharmaceuticals Q2 Adj $(0.31) Beats $(0.42) Estimate, Sales $5.18M Beat $4.37M Estimate

Author: Benzinga Newsdesk | August 14, 2024 07:47am
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.42) by 26.19 percent. This is a 47.62 percent decrease over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $5.18 million which beat the analyst consensus estimate of $4.37 million by 18.47 percent. This is a 2.74K percent increase over sales of $182.00 thousand the same period last year.

Posted In: VRCA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist